Data from the St. Jude lifetime cohort study (St. Jude LIFE) revealed that two common biomarkers of cardiac function and damage could better predict cardiomyopathy within five years than routine clinical evaluations in high-risk, asymptomatic childhood cancer survivors.
FDA delays decision on Applied Therapeutics’ rare metabolic disease drug
The FDA has pushed back its decision date on Applied Therapeutics’ treatment for classic galactosemia to the end of November, the biotech announced Thursday. The
April 2, 2024